Low-Cost, Single Sample Blood Test Detects Different Cancers, Liver Disorders, and Other Diseases

Why It Matters

A single affordable assay that simultaneously screens for diverse diseases could reshape early‑diagnosis pathways, lowering costs and improving patient outcomes across oncology and hepatology.

Key Takeaways

• MethylScan enriches hypermethylated cfDNA, cutting sequencing cost
• Detects 63% of cancers, 55% early-stage at 98% specificity
• Identifies tissue origin, guiding follow‑up diagnostics
• Distinguishes liver disease subtypes with ~85% accuracy
• Single test costs under $20 per sample

Pulse Analysis

Liquid biopsy technologies have long sought a balance between breadth of detection and affordability. Traditional cfDNA tests focus on tumor‑specific mutations, requiring deep sequencing that drives up costs and limits clinical utility. MethylScan flips this paradigm by targeting DNA methylation patterns—tissue‑specific epigenetic marks that shift in disease. Using methylation‑sensitive restriction enzymes to remove unmethylated fragments, the method enriches signals from solid organs, slashing the required sequencing depth to 300× and keeping data generation under five gigabases. This technical shortcut translates into a per‑sample price tag below $20, positioning the assay as a viable option for routine health monitoring.

Clinical validation across more than a thousand individuals demonstrates the assay’s robustness. At 98% specificity, MethylScan identified 63% of cancers across stages and captured 55% of early‑stage tumors, a critical metric for improving survival rates. Its ability to pinpoint the tissue of origin enables clinicians to direct imaging or biopsies efficiently, reducing diagnostic ambiguity. Moreover, the test distinguished between viral hepatitis, alcohol‑related liver disease, and metabolic‑associated liver disease with roughly 85% accuracy, suggesting a broader role beyond oncology and a potential to replace invasive liver biopsies in many scenarios.

The broader market implications are significant. A single, inexpensive blood test that screens for multiple pathologies could accelerate the adoption of population‑level screening programs, especially in resource‑constrained settings. While larger prospective trials are needed to confirm real‑world performance, the cost advantage and multi‑disease coverage align with the industry’s push toward universal early‑detection platforms. Investors and healthcare systems alike are likely to watch MethylScan closely as it moves toward commercialization, potentially reshaping the landscape of preventive medicine and solid‑organ disease surveillance.